Dr Tristan Barber, Dr Christoph Boesecke Two experts discuss best practices for antiretroviral therapy (ART) selection for people living with HIV. Introduction 1. How do different regimens compare in terms of efficacy, particularly considering three- vs two-drug regimens? 2. What are the main considerations in terms of side effects for recommended ART regimens, and how […]
Prof. Anne-Mieke Vandamme, Prof. José Arribas, Prof. Antonella Castagna Watch three experts describe the HIV life cycle, the rationale for ART and how to manage ART resistance. The virology of HIV and the basis of viral replication The biological basis and rationale for multidrug ART regimens Understanding resistance to ART and how to manage it
In this episode, we explore how point-of-care testing is transforming the management of sexually transmitted infections (STIs). Joined by Dr Libby van Gerwen, we discuss the rising global STI rates and the role these innovative tests play in addressing the issue. We also explore the challenges current point-of-care tests face and how next-generation advancements could further transform the future of STI diagnosis and treatment.
Prof. Anne-Mieke Vandamme, Prof. José Arribas, Prof. Antonella Castagna Watch three experts describe the HIV life cycle, the rationale for ART and how to manage ART resistance. The virology of HIV and the basis of viral replication The biological basis and rationale for multidrug ART regimens Understanding resistance to ART and how to manage it
Education, Conference Coverage and Articles
In this episode, we explore how point-of-care testing is transforming the management of sexually transmitted infections (STIs). Joined by Dr Libby van Gerwen, we discuss the rising global STI rates and the role these innovative tests play in addressing the issue. We also explore the challenges current point-of-care tests face and how next-generation advancements could further transform the future of STI diagnosis and treatment.
Highlights Determining infection and multidrug resistance (MDR) rates continuously helps to detect the problem to be solved, including outbreaks. Cleaning and disinfection play an important role in preventing MDR and evaluating and correcting the process for better results. MDR control ...
Two experts discuss best practices for antiretroviral therapy (ART) selection for people living with HIV.
Watch three experts describe the HIV life cycle, the rationale for ART and how to manage ART resistance.
Sponsored content from GSK. Watch leading experts Jeremy Szeto and Kristen Robillard discuss their personal experience with adult immunization programs and the approaches they use in their practices to help optimize adult immunization rates.
Share your knowledge, influence clinical practices and enhance patient care in Infectious Diseases today!
The expansion of HIV treatment access during the past two decades, particularly in low- and middle-income countries, stands as a significant accomplishment in the field of public health.1Â Currently, there are an estimated 30 million people on antiretroviral treatment for HIV ...
Respiratory syncytial virus (RSV) is often of increased concern in the autumn and winter months, especially for women who are pregnant, or those with newborns.1Â Worldwide, RSV is the second leading cause of death (second to malaria) in children during ...
Vaginal symptoms are one of the most common reasons for women accessing acute healthcare in the USA.1Â Vaginitis is most commonly evaluated based on clinical observations, including assessment of discharge characteristics, vaginal pH and, in some settings, microscopic examination of ...
We are excited to introduce the latest edition of touchREVIEWS in Infectious Diseases. Our mission is to bring you thought-provoking interviews, reviews, editorials, case studies and original research within the realm of infectious diseases. We aspire to engage infectious disease ...
The treatment of people with HIV (PWH)/hepatitis B virus (HBV) co-infection, especially those who have additional comorbidities requiring multiple drug therapies can be problematic. Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is a co-formulated medication consisting of two components ...
By sharing, listening and gaining an understanding of the real-life experiences of individuals living with a condition, clinicians and patients can better work together to improve care and outcomes and shape the healthcare system and policy of the future. Patient ...
Despite being the most severe form of viral hepatitis, there is no FDA-approved therapy for chronic hepatitis delta (CHD).1 Patients with CHD can progress to cirrhosis, as early as 5–10 years after infection. Further complications can also develop, such as esophageal ...
Article highlights Erythrasma is a common chronic superficial cutaneous bacterial infection caused by Corynebacterium minutissimum when conditions are conducive. Corynebacterium minutissimum produces coproporphyrin III (a phosphor) that emits a coral pink fluorescence under Wood’s lamp and helps confirm the ...
HIV is a significant global health issue for which there is no cure. However, the availability of antiretroviral therapy (ART) has made it possible to effectively treat and prevent HIV infection, leading to a considerable decrease in associated deaths and ...
Heavily treatment-experienced people living with HIV (HTE-PLWH) represent a minority of those living with HIV.1Â While there is variability in the definitions of HTE-PLWH, its prevalence is estimated to be between 1 and 10% of the total number of people living with ...
Watch three experts discuss how to optimize antiretroviral therapy for people living with HIV through an individualized approach to care
The Russian invasion of Ukraine represents the largest humanitarian crisis that Europe has faced in decades. In the first 4 months of the war, over 9.9 million refugees crossed the Ukrainian border, and over 6.1 million Ukrainian refugees were registered across Europe.1Â Before ...
Introducing the Editorial Board of touchREVIEWS in Infectious Diseases, who support our mission to advance medical knowledge and practice by ensuring the integrity, relevance, and impact of the content we publish. Together, we strive to foster a vibrant academic community and contribute to the continuous improvement of healthcare worldwide.
HIV
Assistant Professor, Division of Infectious Diseases, Rutgers New Jersey Medical School, Newark, NJ, USA
Amesika Nyaku, MD MS is an Assistant Professor in the Division of Infectious Diseases at Rutgers New Jersey Medical School and a physician-scientist. She provides clinical care for people living with HIV or other infectious diseases and substance use disorders. Her research interests lie at the intersection of HIV and substance use disorders. She focuses on 1) evaluating long-acting therapeutics for HIV and opioid use disorder, 2) the implementation of integrated care models for HIV and substance use disorders to improve health outcomes, and 3) increasing the inclusion and participation of racial/ethnic minorities in clinical trials research. She is also co-director of the Northern New Jersey Medication-Assisted Treatment Center of Excellence that is tasked with assisting the state in expanding access to medication-assisted treatment for opioid use disorder through education, novel service delivery and community collaboration.
Sexually Transmitted Infections
Assistant Professor, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA
Dr Olivia Van Gerwen completed her internal medicine residency and chief residency at Tulane University in New Orleans, LA. She returned to her hometown of Birmingham, AL to pursue a fellowship in Infectious Diseases at UAB, which she completed in 2020 in addition to a post-doctoral fellowship in health services, outcomes, and effectiveness research. She is now an Assistant Professor in the University of Alabama at Birmingham (UAB) Division of Infectious Diseases. Olivia’s research focuses on HIV and STI prevention as well as comprehensive sexual health promotion among LGBTQ+ populations. Clinically, she enjoys providing sexual healthcare services to patients at the UAB Gender Health clinic, patients living with HIV at the UAB 1917 Clinic and is the Assistant Medical Director at the UAB Vaginitis Clinic.
Vaccines
Associate Director of the Vaccine and Gene Therapy Institute, Senior Scientist in the Pathobiology and Immunology Division of the Oregon National Primate Research Center, and Professor in the Oregon Health & Science University’s Departments of Pathology and Molecular Microbiology and Immunolog, Portland, OR, USA
Dr Louis J Picker is currently the Associate Director of the Vaccine and Gene Therapy Institute, a Senior Scientist in the Pathobiology and Immunology Division of the Oregon National Primate Research Center, and a Professor in the Oregon Health & Science University’s Departments of Pathology and Molecular Microbiology and Immunology. Dr Picker was recruited to OHSU in 2000 from the Department of Pathology at the University of Texas Southwestern Medical Center at Dallas where he served as a Principal Investigator, Medical Director of the Flow Cytometry and Clinical Immunology Laboratory, and Co-Director of the Division of Hematopathology and Immunology. He received his medical degree at the University of California, San Francisco in 1982, did an internship, residency, and chief residency in Anatomic and Clinical Pathology at the Beth Israel Hospital and Harvard Medical School in Boston, Massachusetts from 1982-86, and received advanced training in Immunopathology and Experimental Pathology at Stanford University Medical Center in Palo Alto, California from 1986-89. Dr Picker is known for his work elucidating human/nonhuman primate (NHP) memory T cell biology, T cell mediated mechanisms of protection against persistent pathogens, the immunopathogenesis of AIDS and tuberculosis, and HIV and TB vaccine development.Â
COVID & HIV
Infectious Diseases Specialist and Senior Lecturer, University of Bonn, Germany
Christoph Boesecke MD completed his medical studies at Charité University in Berlin, Germany. He received his Doctorate in Medicine from the University of Hamburg, Germany for his research in acute HIV infection. He held a 2-year postgraduate position studying integrase inhibitors in acute and chronic HIV infection at the National Centre in HIV Epidemiology and Clinical Research (now The Kirby Institute) in Sydney, Australia. He is currently working as an Infectious Diseases Specialist and Senior Lecturer at the University of Bonn, Germany. His main areas of research are focused on co-morbidities and co-infections in HIV including Covid-19 and monkeypox.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.